+208.6%
BBY vs GSK
+97.4%
+111.2%
-52.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -0.1% | -1.2% | -1.3% |
| 7D | -5.9% | -5.3% | -0.5% | -4.2% |
| 30D | +4.1% | -3.7% | +7.7% | +5.4% |
| 3M | +15.5% | -7.3% | +22.7% | +18.3% |
| 6M | +64.5% | -4.2% | +68.7% | +66.3% |
| YTD | +52.1% | +0.9% | +51.3% | +50.5% |
| 1Y | +39.8% | +7.3% | +32.6% | +35.6% |
| 3Y | +66.4% | +52.7% | +13.7% | +38.3% |
| 5Y | -9.1% | +40.1% | -49.2% | -23.7% |
| All | +208.6% | +97.4% | +111.2% | +122.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling